author-photo

Kenjiro Aogi

8

Papers

821

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (56)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2017 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (282)
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.

2014 International Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (38)
A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance

2014 Breast Cancer
Show All
- Source
- Cite
- Save
Citations (12)
A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI)

2014 Esophagus
Show All
- Source
- Cite
- Save
Citations (22)
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

2009 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (346)
Identification of Predictive Biomarkers for Response to Trastuzumab Using Plasma FUCA Activity and N-Glycan Identified by MALDI-TOF-MS

2009 Journal of Proteome Research
Show All
- Source
- Cite
- Save
Citations (24)